from CLL11 (n = 132), CLL1 (n = 3), CLL5 (n = 1), CLL7 (n = 3), CLL8(n = 2), CLL9 (n = 9), and CLL10 (n = 2). Median age was 82 years (range [80][81][82][83][84][85][86][87][88][89][90]. Concomitant diseases were present in 99% of the pts and median cumulative illness rating scale (CIRS) score was 8 (0-18).Median creatinine clearance was 46 mL/min (range 17-99 mL/min).Distribution of CLL-IPI risk groups was as follows: 6% low, 19% intermediate, 61% high, and 14% very high. Most pts had Binet stage B (36%) or C (43%).Chemoimmunotherapy with chlorambucil plus obinutuzumab (CLB-OB) or chlorambucil plus rituximab (CLB-R) was administered to 61 (40%) and 56 (37%) pts, respectively. Remaining pts received chlorambucil alone (CLB, n = 19), fludarabine (F, n = 10), F/cyclophosphamide (FC, n = 1), FC/rituximab (FCR, n = 2), or bendamustine/rituximab (BR, n = 3). Rates of grade 3 or 4 neutropenia and infections were 35% and 13%, respectively. Premature treatment discontinuations occurred in 15% of cases and were mostly due to adverse events. The total overall response rate was 92% with 13% Results: A decline in age-standardized incidence until the mid-1990s was primarily driven by males >50 years. There was, however, evidence of a slight increase in incidence among children and young adults (≤34 years). The 1-year RSRs (95% confidence interval; CI)for males aged 55, 65, 75, and 85, diagnosed
